Form 4: DocuSign Director Plans Future Share Sale Under 10b5-1

DocuSign Director Anna Marrs reported a planned sale of 728 shares of common stock for $80.3 per share, scheduled for September 15, 2025, under a Rule 10b5-1 plan.

Summary

• DocuSign Director Anna Marrs reported a planned sale of 728 shares of common stock.
• The transaction is scheduled to occur on September 15, 2025, at a price of $80.3 per share.
• This sale is being conducted pursuant to a Rule 10b5-1 trading plan adopted by Ms. Marrs.
• Following this planned transaction, Ms. Marrs is expected to beneficially own 10,799 shares of DocuSign common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled insider share sale under a 10b5-1 plan, which is generally considered a neutral event for company sentiment as it's often for personal financial planning rather than a signal about company performance.

Future Outlook

The filing reports a planned future transaction under a Rule 10b5-1 plan, indicating a pre-scheduled sale of shares by a director. It does not provide any forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This filing represents a routine insider transaction, specifically a planned sale of shares by a director under a Rule 10b5-1 plan. Such transactions are common across publicly traded companies and are typically for personal financial management rather than a reflection of specific company-related news or industry trends.

Stakeholder Impact

• Shareholders: A planned, routine insider sale under a 10b5-1 plan typically has minimal impact on shareholder sentiment or the company's stock price, as it is a pre-arranged personal financial decision.

Key Dates

Recommendation

The filing reports a planned, pre-scheduled sale of shares by a director under a Rule 10b5-1 plan, with the transaction date set for September 15, 2025. This type of future-dated transaction is generally for personal financial planning and is not indicative of a change in company fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

DocuSign, DOCU, Form 4, Insider Trading, Share Sale, Anna Marrs, 10b5-1 Plan, Director